Role of Medical Imaging in Cancers
undefined
Saved in:
| Other Authors: | , |
|---|---|
| Format: | Book Chapter |
| Published: |
Basel, Switzerland
MDPI - Multidisciplinary Digital Publishing Institute
2021
|
| Subjects: | |
| Online Access: | Get Fullteks DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| LEADER | 05854naaaa2202029uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_68462 | ||
| 005 | 20210501 | ||
| 020 | |a books978-3-0365-0181-9 | ||
| 020 | |a 9783036501802 | ||
| 020 | |a 9783036501819 | ||
| 024 | 7 | |a 10.3390/books978-3-0365-0181-9 |c doi | |
| 041 | 0 | |a English | |
| 042 | |a dc | ||
| 072 | 7 | |a M |2 bicssc | |
| 100 | 1 | |a Fanti, Stefano |4 edt | |
| 700 | 1 | |a Evangelista, Laura |4 edt | |
| 700 | 1 | |a Fanti, Stefano |4 oth | |
| 700 | 1 | |a Evangelista, Laura |4 oth | |
| 245 | 1 | 0 | |a Role of Medical Imaging in Cancers |
| 260 | |a Basel, Switzerland |b MDPI - Multidisciplinary Digital Publishing Institute |c 2021 | ||
| 300 | |a 1 electronic resource (312 p.) | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a undefined | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine |2 bicssc | |
| 653 | |a positron emission tomography | ||
| 653 | |a head and neck neoplasms | ||
| 653 | |a neovascularization | ||
| 653 | |a pathologic | ||
| 653 | |a PET/CT | ||
| 653 | |a urothelial carcinoma | ||
| 653 | |a bladder cancer | ||
| 653 | |a upper tract urothelial carcinoma | ||
| 653 | |a survival | ||
| 653 | |a PET | ||
| 653 | |a PSMA | ||
| 653 | |a prostate | ||
| 653 | |a DCFPyL | ||
| 653 | |a DCFBC | ||
| 653 | |a PSMA-1007 | ||
| 653 | |a ovarian cancer | ||
| 653 | |a relapse | ||
| 653 | |a SUVmax | ||
| 653 | |a targeted therapy | ||
| 653 | |a prognosis | ||
| 653 | |a soft tissue sarcoma (STS) | ||
| 653 | |a pazopanib | ||
| 653 | |a dynamic 18F-FDG PET/CT | ||
| 653 | |a SUV | ||
| 653 | |a two-tissue compartment model | ||
| 653 | |a magnetic resonance imaging | ||
| 653 | |a machine learning | ||
| 653 | |a diffusion | ||
| 653 | |a perfusion | ||
| 653 | |a texture analysis | ||
| 653 | |a squamous cell carcinoma of the head and neck | ||
| 653 | |a diffusion-weighted imaging | ||
| 653 | |a malignant pleural mesothelioma | ||
| 653 | |a pleural dissemination | ||
| 653 | |a empyema | ||
| 653 | |a pleural effusion | ||
| 653 | |a mCRPC | ||
| 653 | |a SPECT/CT | ||
| 653 | |a Computer-assisted diagnosis | ||
| 653 | |a XOFIGO | ||
| 653 | |a Therapy response assessment | ||
| 653 | |a circulating miRNAs | ||
| 653 | |a breast cancer | ||
| 653 | |a imaging parameters | ||
| 653 | |a PET/MRI | ||
| 653 | |a biomarkers | ||
| 653 | |a triple negative breast cancer | ||
| 653 | |a VCAM-1 | ||
| 653 | |a SPECT imaging | ||
| 653 | |a sdAbs | ||
| 653 | |a Hounsfield unit | ||
| 653 | |a computed tomography | ||
| 653 | |a adipose tissue | ||
| 653 | |a precision oncology | ||
| 653 | |a FDG-PET/CT | ||
| 653 | |a PERCIST | ||
| 653 | |a metastatic breast cancer | ||
| 653 | |a prostate cancer | ||
| 653 | |a 18F-FACBC | ||
| 653 | |a recurrence | ||
| 653 | |a meta-analysis | ||
| 653 | |a review | ||
| 653 | |a meningioma | ||
| 653 | |a somatostatin receptor | ||
| 653 | |a neuroimaging | ||
| 653 | |a radionuclide therapy | ||
| 653 | |a breast | ||
| 653 | |a imaging | ||
| 653 | |a marker | ||
| 653 | |a radiomics | ||
| 653 | |a Yin Yang 1 | ||
| 653 | |a PDAC | ||
| 653 | |a Mesothelin | ||
| 653 | |a noninvasive imaging | ||
| 653 | |a receptor status | ||
| 653 | |a molecular imaging | ||
| 653 | |a nuclear medicine | ||
| 653 | |a guidelines | ||
| 653 | |a overutilization | ||
| 653 | |a epistemology | ||
| 653 | |a consensus | ||
| 653 | |a mantle cell lymphoma | ||
| 653 | |a 18F-FDG PET/CT | ||
| 653 | |a Deauville criteria | ||
| 653 | |a Radium-223 | ||
| 653 | |a FDG | ||
| 653 | |a castrate resistant prostate cancer | ||
| 653 | |a programmed cell death 1 receptor | ||
| 653 | |a diagnostic imaging | ||
| 653 | |a CTLA-4 Antigen | ||
| 653 | |a Immunotherapy | ||
| 653 | |a Adoptive | ||
| 653 | |a radioactive tracers | ||
| 653 | |a radionuclide imaging | ||
| 653 | |a CD8-Positive T-Lymphocytes | ||
| 653 | |a PI-RADS | ||
| 653 | |a diffusion kurtosis imaging | ||
| 653 | |a dynamic contrast-enhanced magnetic resonance imaging | ||
| 653 | |a 68Gallium-PSMA PET/CT | ||
| 653 | |a prostate-specific-antigen | ||
| 653 | |a PSA kinetics thresholds | ||
| 653 | |a biochemical recurrence | ||
| 653 | |a optimal cutoff level | ||
| 653 | |a non-small-cell lung cancer | ||
| 653 | |a circulating tumor cells | ||
| 653 | |a immunotherapy | ||
| 653 | |a response to treatment | ||
| 653 | |a head and neck cancer | ||
| 653 | |a HPV | ||
| 653 | |a EBV | ||
| 653 | |a p16 | ||
| 653 | |a Molecular imaging | ||
| 653 | |a miRNA expression | ||
| 653 | |a radiogenomics | ||
| 653 | |a radiomic | ||
| 653 | |a diagnosis | ||
| 653 | |a biomarker | ||
| 653 | |a glioblastoma | ||
| 653 | |a radiation therapy | ||
| 653 | |a MRI | ||
| 653 | |a diffusion tensor imaging | ||
| 653 | |a Hodgkin lymphoma | ||
| 653 | |a diffuse large B-cell lymphoma | ||
| 653 | |a staging | ||
| 653 | |a response assessment | ||
| 653 | |a locally advanced cervical cancer | ||
| 653 | |a concurrent chemoradiotherapy | ||
| 653 | |a treatment response | ||
| 653 | |a follow up | ||
| 653 | |a cystic tumor | ||
| 653 | |a International Consensus Guidelines | ||
| 653 | |a intraductal papillary mucinous neoplasms | ||
| 653 | |a pancreatic neoplasms | ||
| 653 | |a PD-1 | ||
| 653 | |a PD-L1 | ||
| 653 | |a response to therapy | ||
| 653 | |a NSCLC | ||
| 653 | |a positron-emission tomography | ||
| 653 | |a single-photon emission computed tomography | ||
| 653 | |a immune checkpoint inhibitors | ||
| 653 | |a gold nanoparticle | ||
| 653 | |a heat shock protein 70 | ||
| 653 | |a spectral-CT | ||
| 653 | |a n/a | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/3480 |7 0 |z Get Fullteks |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/68462 |7 0 |z DOAB: description of the publication |